Using CDK4/6 Inhibitors to Manage HR-Positive Metastatic Breast Cancer

Slides:



Advertisements
Similar presentations
Ibrance® - Palbociclib
Advertisements

Breast Cancer: Follow up and Management of recurrence Carol Marquez, M.D. Associate Professor Department of Radiation Medicine OHSU.
These slides were released by the speaker for internal use by Novartis.
CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 Phase II MONARCH 1: CDK4/6 Inhibitor Abemaciclib in HR+/HER2- MBC.
CCO Independent Conference Coverage
CDK 4 and 6 Inhibitors in HR-Positive Advanced Breast Cancer: Assessing New Data.
Where Are We on the Path to Elimination of Chronic Hepatitis C?
CCO Independent Conference Coverage
Individualizing Treatment Options in Advanced ER-Positive Breast Cancer.
THBT neoadjuvant endocrine therapy is to be used in post-menopausal breast cancer woman Antonino Grassadonia Università «G. D’Annunzio» – Chieti-Pescara.
Optimizing Combination Endocrine Therapy in HR-Positive Advanced Breast Cancer.
Presented By Luca Malorni at 2017 ASCO Annual Meeting
Endocrine Combinations in HR-Positive MBC: The Future Is Now
Evolving Paradigms in the Management of HR-Positive Breast Cancer
CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: Implementing Paradigms in Clinical Practice.
The Nurse View: Hormone Receptor-Positive Advanced Breast Cancer
Expanding Horizons in the Clinical Care of ER-Positive, HER2-Negative Metastatic Breast Cancer.
Perspectives on Triple-Negative Breast Cancer
Gout Management.
A Paradigm Shift From One-Size-Fits-All to Tailor-Made Therapy for Metastatic Colorectal Cancer.
CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: A Clinical Update
New Patient Journeys in Non-small cell lung cancer
The Nurse View.
سرطان الثدي Breast Cancer
Ask the Onychomycosis Expert, Part 2
Program Goals. Implementing the Updated American Thyroid Association Guidelines and Recommendations for RAI-R DTC.
Individualizing Treatment Options in Advanced ER-Positive Breast Cancer.
Program Goals. Targeting New Pathways for Overcoming Endocrine Resistance in Breast Cancer.
Improving Acne Outcomes
Navigating New Treatment Landscapes in HR-Positive, HER2-Negative Metastatic Breast Cancer.
The Nurse View: Updates in the Management of Metastatic Colorectal Cancer.
Before and After: Patient Cases in Onychomycosis
Differentiating Among the CDK 4/6 Inhibitors in the Management of Metastatic Breast Cancer.
Clinical Considerations in Evidence-based Management of GIST
CDK4/6 Inhibitors in Breast Cancer:
CDK 4 and 6 Inhibitors in HR-Positive Advanced Breast Cancer: Assessing New Data.
CDK4/6 Inhibitors in Practice
Optimizing Management of Advanced Bladder Cancer
Case Study. Managing Medication and Adherence in SIHD: Partnering With the Patient to Improve Care.
Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: First-line Considerations.
The Nurse View: Targeted Therapies for the Patient With Metastatic Colorectal Cancer.
Treatment of HR+ Breast Cancer: A Clinical Update
From Symptom Management to Communication in Advanced GI Cancers
Program Goals. Single vs Dual HER2 Blockade for Metastatic HER2-Positive Breast Cancer.
A Better Solution For Cancer Patients With VTE?
Hormone Receptor-Positive Advanced Breast Cancer:
Program Goals. Implementing the Updated American Thyroid Association Guidelines and Recommendations for RAI-R DTC.
Managing Adverse Events With New Oral Therapies in CLL
Advancing the Treatment of IBD With Biologics
Program Goals Overview Is NEDA a Reasonable Target?
The Road to Quality Improvement in HER2-Positive Breast Cancer
Hormone Receptor-Positive Advanced Breast Cancer Introduction
Introduction Advanced Hormone Receptor-Positive Breast Cancer
ABSTRACT ABCSG 6a MA17-1 MA.17R NSABP B-33. Extended Adjuvant Therapy With Aromatase Inhibitor Among Postmenopausal Breast Cancer.
Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: Considerations for Previously Treated Disease.
New Paradigms in HR-Positive Advanced Breast Cancer
Optimizing Treatment in HR-Positive Breast Cancer: A Case-Based Discussion.
Extraordinary Cases in VTE
Program Goals Overview Is NEDA a Reasonable Target?
Navigating New Treatment Landscapes in HR+ HER2-Negative Advanced Breast Cancer.
Selecting Treatment Approaches in Hemophilia
Early and locally advanced breast cancer
Optimizing Front-Line Endocrine Therapy in Metastatic Breast Cancer
Clinical Considerations in Evidence-based Management of GIST
CDK4/6 Inhibitors.
Real-World Evidence.
What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer
Clinical Pearls in the Management of Patients With Advanced Non-Small Cell Lung Cancer.
Maximizing Disease-Free Survival in Early-Stage HER2-Positive Breast Cancer.
Mitigating Side Effects and Optimizing Compliance With Oral Therapies in CLL.
Presentation transcript:

Using CDK4/6 Inhibitors to Manage HR-Positive Metastatic Breast Cancer

HR-Positive Breast Cancer

Epidemiology of HR-Positive Breast Cancer

Common Therapies for HR-Positive Breast Cancer

Relapsed and Metastatic Disease

NCCN Guidelines for Treatment of Recurrent or Stage IV Disease in Postmenopausal Women

MOA for CDK4/6 Inhibitors

HR+/HER2- Advanced/MBC

Endocrine Therapy Side Effects

CDK4/6 Inhibitor Side Effects

Cardiotoxicity Monitoring For Patients Treated With Ribociclib

CDK4/6 Inhibitor Drug Drug/Food Interactions

Neutropenia Associated With CDK4/6 Inhibitors

Neutropenia Monitoring

Strategies for Optimizing Adherence to Oral Therapies

Managing Treatment-Related AEs

Summary

Abbreviations

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com. Inc. All rights reserved.